Peptide Library
Searchable, scored, and cited. Every peptide page pulls live data from institutional sources (FDA, NIH, EMBL-EBI). Browse by goal below or filter by evidence quality.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
Semaglutide
Fat LossGLP-1 receptor agonist with extensive Phase 3 trial data for type 2 diabetes and chronic weight management. Prescription-only in most jurisdictions.
Tirzepatide
Fat LossDual GIP / GLP-1 receptor agonist with strong Phase 3 evidence in type 2 diabetes (SURPASS) and obesity (SURMOUNT).
Retatrutide
Fat LossEli Lilly's triple agonist (GLP-1 / GIP / glucagon receptor). Currently the most potent weight-management investigational drug — Phase 2 trials reported ~24% body weight reduction at the highest dose. Phase 3 TRIUMPH program ongoing. Not yet FDA-approved.
Liraglutide
Fat LossDaily GLP-1 receptor agonist (Saxenda/Victoza). FDA-approved for chronic weight management and type 2 diabetes. Older sibling of semaglutide with smaller weight-loss effect size.
Orforglipron
Fat LossEli Lilly's once-daily ORAL non-peptide GLP-1 receptor agonist (LY3502970). The first oral small-molecule GLP-1 with no food/water restrictions (unlike Rybelsus). Phase 3 ACHIEVE program for diabetes and ATTAIN for obesity both ongoing.
Tesamorelin
Fat LossGHRH analog (Egrifta) FDA-approved for HIV-associated lipodystrophy. Studied for visceral adiposity reduction outside that indication.
CJC-1295 / Ipamorelin
MuscleGrowth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.
IGF-1 LR3
MuscleInsulin-like Growth Factor 1, Long R3 variant — an analog of human IGF-1 with extended half-life (~20-30 hours vs. ~12 minutes for native IGF-1). Used in research; widely (and controversially) discussed in performance-enhancement communities. NOT FDA-approved for human use; the only approved IGF-1 product is mecasermin (native sequence).
MOTS-c
LongevityMitochondrial-derived peptide encoded in the 12S rRNA. Preclinical data on insulin sensitivity, exercise capacity, and metabolic health. No FDA approval. Human data limited to small studies.
5-Amino-1MQ
Fat LossSmall-molecule NNMT inhibitor (NOT a peptide — it's a quinoline derivative). NNMT (nicotinamide N-methyltransferase) is upregulated in obese white adipose tissue. Preclinical studies show 5-Amino-1MQ reduces adipocyte size and improves metabolic markers in obese mice. No human RCTs. Sold as a research chemical.